Jonathan D. Cheng, MD, discusses advances with immunotherapy-based combinations in oncology.
Jonathan D. Cheng, MD
Advertisement
Articles by Jonathan D. Cheng, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
3
TP53 Co-Mutations and Prognosis in EGFR-Mutated NSCLC
4
Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC
5